Low Molecular Weight Heparin Vs No Treatment in Pregnant Women With Previous Preeclampsia or Fetal Growth Restriction Who Were Heterozygote for Factor V Leiden or Prothrombin Gene G20210A Mutation
试验速览
- 阶段
- 不适用
- 状态
- 终止
研究概览
简要总结
The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both.
详细描述
The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. We also will assess the effect of treatment on other indicators of maternal and neonatal complications, and the growth of fetal body composition in terms of fat and lean body mass.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Previous severe preeclampsia
- •Previous severe fetal growth restriction
- •Heterozygous Factor V Leiden
- •Heterozygous G20210A prothrombin gene mutations
排除标准
- •renal disease
- •chronic hypertension
- •preexisting diabetes mellitus
- •homozygosity for Factor V Leiden
- •homozygosity for prothrombin G20210A mutation
- •hyperhomocysteinemia
- •protein C deficency
- •protein S deficency
- •antithrombin deficiency
- •positive anticardiolipin antibodies
- •positive lupus anticoagulant